Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RVMD · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
65
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Revolution Medicines, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
RVMD insider buying and selling by quarter
RVMD insider selling · RVMD insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · RVMD ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
RVMD executive sell shares · RVMD board member insider trading · RVMD insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 26, 2026 | Mancini Anthony See Remarks | Option | 3,121 | $105K | Form 4 |
| May 26, 2026 | Mancini Anthony See Remarks | Sale | 700 | $107K | Form 4 |
| May 26, 2026 | Mancini Anthony See Remarks | Sale | 2,000 | $308K | Form 4 |
| May 26, 2026 | Mancini Anthony See Remarks | Sale | 421 | $65K | Form 4 |
| Apr 27, 2026 | Mancini Anthony See Remarks | Option | 3,120 | $105K | Form 4 |
| Apr 27, 2026 | Mancini Anthony See Remarks | Sale | 1,671 | $220K | Form 4 |
| Apr 27, 2026 | Mancini Anthony See Remarks | Sale | 1,049 | $139K | Form 4 |
| Apr 27, 2026 | Mancini Anthony See Remarks | Sale | 400 | $54K | Form 4 |
| Apr 15, 2026 | GOLDSMITH MARK A See Remarks · Director | Option | 96,756 | $458K | Form 4 |
| Apr 15, 2026 | GOLDSMITH MARK A See Remarks · Director | Option | 23,244 | $95K | Form 4 |
| Apr 15, 2026 | GOLDSMITH MARK A See Remarks · Director | Sale | 120,000 | $18.01M⚡ | Form 4 |
| Mar 25, 2026 | Mancini Anthony See Remarks | Option | 37,450 | $1.26M⚡ | Form 4 |
| Mar 25, 2026 | Mancini Anthony See Remarks | Sale | 1,800 | $168K | Form 4 |
| Mar 25, 2026 | Mancini Anthony See Remarks | Sale | 3,128 | $295K | Form 4 |
| Mar 25, 2026 | Mancini Anthony See Remarks | Sale | 21,086 | $2.01M⚡ | Form 4 |
| Mar 25, 2026 | Mancini Anthony See Remarks | Sale | 11,036 | $1.06M⚡ | Form 4 |
| Mar 25, 2026 | Mancini Anthony See Remarks | Sale | 400 | $39K | Form 4 |
| Mar 17, 2026 | Wei Lin Chief Medical Officer | Sale | 2,073 | $206K | Form 4 |
| Mar 17, 2026 | Kelsey Stephen Michael See Remarks | Sale | 4,302 | $428K | Form 4 |
| Mar 17, 2026 | GOLDSMITH MARK A See Remarks · Director | Sale | 12,871 | $1.28M⚡ | Form 4 |
| Mar 17, 2026 | Horn Margaret A COO | Sale | 4,583 | $456K | Form 4 |
| Mar 17, 2026 | Anders Jack CFO | Sale | 2,753 | $274K | Form 4 |
| Mar 17, 2026 | Cislini Jeff General Counsel | Sale | 1,795 | $179K | Form 4 |
| Mar 19, 2026 | Cislini Jeff General Counsel | Sale | 1,163 | $113K | Form 4 |
| Mar 17, 2026 | Wang Xiaolin See Remarks | Sale | 2,010 | $200K | Form 4 |
GOLDSMITH MARK A
See Remarks · Director
Date
Apr 15
Shares
96,756
Price
$4.73
Value
$458K
GOLDSMITH MARK A
See Remarks · Director
Date
Apr 15
Shares
23,244
Price
$4.09
Value
$95K
GOLDSMITH MARK A
See Remarks · Director
Date
Apr 15
Shares
120,000
Price
$150.09
Value
$18.01M ⚡
Mancini Anthony
See Remarks
Date
Mar 25
Shares
37,450
Price
$33.62
Value
$1.26M ⚡
Kelsey Stephen Michael
See Remarks
Date
Mar 17
Shares
4,302
Price
$99.48
Value
$428K
GOLDSMITH MARK A
See Remarks · Director
Date
Mar 17
Shares
12,871
Price
$99.48
Value
$1.28M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RVMD insider trading
RVMD insider trades
Revolution Medicines, Inc. (RVMD) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including GOLDSMITH MARK A (See Remarks · Director), Mancini Anthony (See Remarks), Horn Margaret A (COO). Over the past 12 months, 5 insiders have filed transactions with the SEC. RVMD insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Revolution Medicines, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RVMD insider trading · 5 questionsThe insiders of Revolution Medicines, Inc. (RVMD) include executives and directors such as GOLDSMITH MARK A (See Remarks · Director), Mancini Anthony (See Remarks), Horn Margaret A (COO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026